The purpose of this study is to determine whether reactivation of latent cytomegalovirus
infection in critically ill patients looked after in the intensive care unit can be
successfully and safely prevented using antiviral agents. Comparison is made between standard
care, and treatment with one of two different antiviral regimens: valaciclovir/aciclovir,
which has a favourable side effect profile but requires high dosage to be effective, and
valganciclovir/ganciclovir, which has more side effects, but has been demonstrated to be
effective in low dosage.
The primary hypothesis is that cytomegalovirus reactivation can be effectively suppressed
with antiviral prophylaxis.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Birmingham NHS Foundation Trust
Collaborator:
National Institute for Health Research, United Kingdom